ArriVent BioPharma, Inc. Common Stock
$29.78
-0.47%ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -6.9).
Valuation inputs: P/E -6.9, earnings yield N/A, momentum -0.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -54.1%, ROIC -57.8%).
Profitability stack: net margin 0.0%, ROE -54.1%, ROIC -57.8%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +7.8%, momentum -0.5%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
ArriVent BioPharma, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
ArriVent BioPharma, Inc. Common Stock Fair Value Envelope
No Revenue Data
AVBP has not reported any revenue values in the available annual periods.
ArriVent BioPharma, Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
AVBP has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
AVBP has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
AVBP has not reported any net profit margin values in the available annual periods.
ArriVent BioPharma, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ArriVent BioPharma, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
ArriVent BioPharma, Inc. Common Stock Street Expectations Map
Wall Street analysts project that AVBP stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 45.00, with estimates ranging from a low of 45.00 to a high of 45.00.
The consensus 1-year price target stands at 45.00, with estimates ranging from a low of 45.00 to a high of 45.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
ArriVent BioPharma, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $15K and sold $12.98M worth of AVBP shares, resulting in $12.97M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
555.6K
12.98M
-13.0M
-$12.98M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
6.5K
14.83K
0
0.00
+15K
+$15K
Top Buyers
Lachapelle Robin
Officer: Chief Operating Officer
$15K
Top Sellers
Hillhouse Investment Management, Ltd.
10 Percent Owner
$12.98M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $12.97M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
No Dividend Yield Data
AVBP has not reported any dividend yield values in the available annual periods.
avbp Dividend History
Learning Layer
Related Guides
Build conviction on AVBP by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.